Ratings by Evercore ISI (Jonathan Miller)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/10/2026 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2026 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2026 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2026 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2026 | Aura Biosciences | AURA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Intellia Therapeutics | NTLA | Maintain | In Line (N/A) |
|
Details | ||
| 11/25/2025 | Aura Biosciences | AURA | New Coverage | Outperform (N/A) |
5.50 (6.99) |
27.09% | Details | |
| 11/11/2025 | Intellia Therapeutics | NTLA | Downgrade | In Line (Outperform) |
9.52 (11.38) |
19.54% | Details | |
| 8/25/2025 | Editas Medicine | EDIT | New Coverage | Outperform (N/A) |
2.80 (2.98) |
6.43% | Details | |
| 8/25/2025 | Aura Biosciences | AURA | New Coverage | Outperform (N/A) |
6.55 (5.50) |
-16.03% | Details | |
| 8/25/2025 | Intellia Therapeutics | NTLA | New Coverage | Outperform (N/A) |
10.52 (9.52) |
-9.51% | Details | |
| 8/25/2025 | Enanta Pharmaceuticals | ENTA | New Coverage | Outperform (N/A) |
8.83 (13.74) |
55.61% | Details | |
| 8/25/2025 | Caribou Biosciences Inc. | CRBU | New Coverage | In Line (N/A) |
1.85 (1.65) |
-10.81% | Details | |
| 4/30/2025 | OnKure Therapeutics Inc. | OKUR | New Coverage | Outperform (N/A) |
2.53 (4.20) |
66.01% | Details | |
| 11/27/2023 | Gracell Biotechnologies Inc | GRCL | New Coverage | Outperform (N/A) |
5.05 (10.25) |
102.97% | Details | |
| 10/11/2023 | RayzeBio | RYZB | New Coverage | Outperform (N/A) |
21.03 (62.49) |
197.15% | Details | |
| 3/31/2023 | Gritstone Oncology | GRTS | New Coverage | Outperform (N/A) |
2.59 (0.03) |
-98.84% | Details | |
| 9/2/2022 | ProKidney Corp. | PROK | New Coverage | Outperform (N/A) |
9.67 (1.62) |
-83.25% | Details | |
| 4/27/2022 | Vaxxinity | VAXX | New Coverage | In Line (N/A) |
3.61 (0.00) |
-100% | Details | |
| 11/24/2021 | Entrada Therapeutics | TRDA | New Coverage | Outperform (N/A) |
24.23 (6.89) |
-71.56% | Details | |
| 7/1/2020 | Gamida Cell Ltd. | GMDA | New Coverage | Outperform (N/A) |
4.46 (0.03) |
-99.33% | Details | |
| 9/12/2019 | Tocagen Inc. | TOCA | Downgrade | In Line (Outperform) |
4.18 (1.26) |
-69.86% | Details |
